Web14 apr. 2024 · InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China … WebThe company was founded in 2024 and is based in Beijing, China. Headquarters Location 3007, 30th Floor, Block 2, China Central Place Office Building, No.79 Jianguo Road, …
Inxmed (Nanjing) Co., Ltd:Financial,Market Cap,Revenue
WebI am the co-founder & CEO of In-Med Prognostics Inc, an AI/ML firm operating in healthcare, wellness, and sports tech space. Our proven capabilities are in translational … WebPrivate. InxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma … phoenix slice house
About_InxMed-Biotech_Pipeline_FAK inhibitor_Biological R&D
Web16 aug. 2024 · The FDA has granted a fast-track designation to IN10018, a selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor, for the treatment of … Web14 apr. 2024 · NANJING, China, April 13, 2024 /PRNewswire/ -- InxMed Co., Ltd. announced that IN10018, its focal adhesion kinase (FAK) inhibitor, had been granted … Web18 okt. 2024 · InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, … how do you get a silver lab